PROTOCOL NRG-DT001 – Cohort A: Temporarily Closed to Accrual


Cohort A Temporarily Closed to Accrual

Cohort A (extremity/body wall) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS)”, is temporarily closed to accrual effectively immediately because 3 patients have been enrolled, which is the maximum allowed per protocol.

 

The cohort A of this trial will be temporarily closed for at least 9 weeks until all 3 patients complete the DLT evaluation period. A broadcast with more details regarding reopening will be sent when all 3 patients have completed the DLT evaluation period. We anticipate cohort A to be open again around mid-May 2019.

 

Note: Cohort B (abdomen/pelvis/retroperitoneum) is still open to accrual to dose level 1. We encourage all investigators to consider this trial for eligible patients.

 

Please distribute this information to the appropriate personnel.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse